ADRIBLASTINA RAPID DISSOLUTION 10mg/5ml Infusion
Doxorubicin Hydrochloride
2mg/ml
PHARMACIA & UPJOHN S.p.A.
| Pack size | 1 vial (Lyophilisate) + 1 Solvent Ampoule (5ml) |
|---|---|
| Dispensing mode | POM |
| Source | ITALY |
| Agent | GULF DRUG EST. |
| Retail Price | 52.00 AED |
Available as:
Indications
ADRIBLASTINA RAPID DISSOLUTION 10mg/5ml Infusion is used for:
AIDS-related Kaposi's sarcoma, Ovarian carcinoma, Metastatic breast carcinoma, bladder carcinoma
Adult Dose
Intravenous
As Doxorubicin liposomal
Kaposi's Sarcoma
Indicated for AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy
20 mg/m² IV q3Weeks
Ovarian Cancer
Indicated for ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy
50 mg/m² IV q4Weeks x 4 courses minimum
Multiple Myeloma
Indicated in combination with bortezomib for multiple myeloma in patients who have not previously received bortezomib and have received at least 1 prior therapy
30 mg/m² IV on day 4 following bortezomib 1.3 mg/m² on days 1, 4, 8 & 11 q3Weeks
Metastatic breast cancer
Adult: 60-75 mg/m2 BSA once every 3 wk in combination with cyclophosphamide given as an infusion over 1 hr diluted in 0.9% sodium chloride or 5% glucose.
Irrigation
Local malignant neoplasms in the bladder
Adult: 50 ml of a 1 mg/ml solution instilled into the bladder for 1 hr once a mth.
Hepatic Impairment
Serum bilirubin <1.2 mg/dL: Dose adjustment not necessary
Serum bilirubin 1.2-3 mg/dL [20.5-51.3 micromoles/L]: Give 50% dose
Serum bilirubin: 3.1-5 mg/dL [53-85.5 micromoles/L]: Give 25% dose
Severe hepatic impairment: Contraindicated
Child Dose
Safety and efficacy not established
Renal Dose
Renal Impairment
Dose adjustment not necessary
Administration
Contra Indications
Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy.
Precautions
Elderly, children, hepatic impairment. Monitor blood counts and ECG.
Lactation: Enters breast milk/not recommended
Pregnancy-Lactation
Pregnancy Category: D
Lactation: Enters breast milk/not recommended
Interactions
Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol.
Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.
Adverse Effects
Side effects of Doxorubicin Hydrochloride :
>10%
Kaposi's Sarcoma
Anemia (>50%), Thrombocytopenia (>50%), Neutropenia (10-50%), Anemia (18.2%), Nausea (17%)
Ovarian cancer
>25%
Hand-foot syndrome (50%), Nausea (46%), Stomatitis (41%), Asthenia (40.2%), Vomiting (32.6%), Rash (28%), Constipation (>25%), Abdominal pain (>25%)
Ovarian cancer
10-25%
Fever (21.3%), Anorexia (20%), Diarrhea (20%), Peripheral edema, Dyspepsia, Pharyngitis, Dyspnea, Alopecia
1-10%
Kaposi's Sarcoma
5-10%
Asthenia (9.9%), Fever (9.1%), Diarrhea (7.8%), Vomiting (7.8%), Stomatitis (6.8%), Rash (1-5%), Alopecia (1-5%), Increased alkaline phosphatase
Kaposi's Sarcoma
1-5%
Hand-foot syndrome (3.4%), Hypotension, Tachycardia, Dyspnea, Hemolysis, Rash
Ovarian cancer (selected)
Neutropenia (13.3%), Anemia (0.4-5.4%), Thrombocytopenia (1.3%)
<1%
Abscess, Acute myeloid leukemia, Cardiomegaly, Cardiomyopathy, Erythema nodosum, Hyperkalemia, Hyperuricemia, Ketosis
Potentially Fatal: Bone marrow suppression, cardiotoxicity.
Mechanism of Action
Doxorubicin is a cytotoxic anthracycline antibiotic. The cytotoxic action results from its binding to DNA and inhibition of nucleic acid synthesis. Doxorubicin has been shown to produce regression in a variety of disseminated malignancies.
Note
ADRIBLASTINA RAPID DISSOLUTION 10mg/5ml 2mg/ml Infusion manufactured by PHARMACIA & UPJOHN S.p.A.. Its generic name is Doxorubicin Hydrochloride. ADRIBLASTINA RAPID DISSOLUTION 10mg/5ml is availble in United Arab Emirates.
Farmaco UAE drug index information on ADRIBLASTINA RAPID DISSOLUTION 10mg/5ml Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.